[1] Thakran S, Guin D, Singh P, Singh P, Kukal S, Rawat C, Yadav S, Kushwaha SS, Srivastava AK, Hasija Y, Saso L,Ramachandran S, Kukreti R. Genetic landscape of common epilepsies:advancing towards precision in treatment[J]. Int J Mol Sci, 2020, 21:7784.
[2] Hildebrand MS, Dahl HH, Damiano JA, Smith RJ, Scheffer IE, Berkovic SF. Recent advances in the molecular genetics of epilepsy[J]. J Med Genet, 2013, 50:271-279.
[3] Perucca P, Bahlo M, Berkovic SF. The genetics of epilepsy[J]. Annu Rev Genomics Hum Genet, 2020, 21:205-230.
[4] Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, Glauser T, Goldstein DB, Han Y, Heinzen EL, Hitomi Y, Howell KB, Johnson MR, Kuzniecky R, Lowenstein DH, Lu YF, Madou MR, Marson AG, Mefford HC, Esmaeeli Nieh S, O'Brien TJ, Ottman R, Petrovski S, Poduri A, Ruzzo EK, Scheffer IE, Sherr EH, Yuskaitis CJ, Abou-Khalil B, Alldredge BK, Bautista JF, Berkovic SF, Boro A, Cascino GD, Consalvo D, Crumrine P, Devinsky O, Dlugos D, Epstein MP, Fiol M, Fountain NB, French J, Friedman D, Geller EB, Glauser T, Glynn S, Haut SR, Hayward J, Helmers SL, Joshi S, Kanner A, Kirsch HE, Knowlton RC, Kossoff EH, Kuperman R, Kuzniecky R, Lowenstein DH, McGuire SM, Motika PV, Novotny EJ, Ottman R, Paolicchi JM, Parent JM, Park K, Poduri A, Scheffer IE, Shellhaas RA, Sherr EH, Shih JJ, Singh R, Sirven J, Smith MC, Sullivan J, Lin Thio L, Venkat A, Vining EP, Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR; Epi4K Consortium, Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopathies[J]. Nature, 2013, 501:217-221.
[5] Symonds JD, Zuberi SM, Johnson MR. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment[J]. Curr Opin Neurol, 2017, 30:193-199.
[6] Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA. Ion channels in genetic epilepsy:from genes and mechanisms to disease-targeted therapies[J]. Pharmacol Rev, 2018, 70:142-173.
[7] Talwar D, Hammer MF. SCN8A epilepsy, developmental encephalopathy, and related disorders[J]. Pediatr Neurol, 2021, 122:76-83.
[8] Verma IC, Bhatia S, Arora V. Genetic testing in pediatric epilepsy[J]. Indian J Pediatr, 2021, 88:1017-1024.
[9] Perucca P, Perucca E. Identifying mutations in epilepsy genes:impact on treatment selection[J]. Epilepsy Res, 2019, 152:18-30.
[10] Hanada T. Ionotropic glutamate receptors in epilepsy:a review focusing on AMPA and NMDA receptors[J]. Biomolecules, 2020, 10:464.
[11] XiangWei W, Jiang Y, Yuan H. De Novo mutations and rare variants occurring in NMDA receptors[J]. Curr Opin Physiol, 2018, 2:27-35.
[12] Myers SJ, Yuan H, Kang JQ, Tan FCK, Traynelis SF, Low CM. Distinct roles of GRIN2A and GRIN2B variants in neurological conditions[J]. F1000Res, 2019, 8:F1000 Faculty Rev-1940.
[13] Mangano GD, Riva A, Fontana A, Salpietro V, Mangano GR, Nobile G, Orsini A, Iacomino M, Battini R, Astrea G, Striano P, Nardello R. De novo GRIN2A variants associated with epilepsy and autism and literature review[J]. Epilepsy Behav, 2022, 129:108604.
[14] Lesca G, Møller RS, Rudolf G, Hirsch E, Hjalgrim H, Szepetowski P. Update on the genetics of the epilepsy-aphasia spectrum and role of GRIN2A mutations[J]. Epileptic Disord, 2019, 21(S1):41-47.
[15] Benke TA, Park K, Krey I, Camp CR, Song R, Ramsey AJ, Yuan H, Traynelis SF, Lemke J. Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs[J]. Neuropharmacology, 2021, 199:108805.
[16] Lalo U, Koh W, Lee CJ, Pankratov Y. The tripartite glutamatergic synapse[J]. Neuropharmacology, 2021, 199:108758.
[17] Amin JB, Moody GR, Wollmuth LP. From bedside-to-bench:what disease-associated variants are teaching us about the NMDA receptor[J]. J Physiol, 2021, 599:397-416.
[18] Pagano J, Giona F, Beretta S, Verpelli C, Sala C. N-methyl-D-aspartate receptor function in neuronal and synaptic development and signaling[J]. Curr Opin Pharmacol, 2021, 56:93-101.
[19] Hansen KB, Wollmuth LP, Bowie D, Furukawa H, Menniti FS, Sobolevsky AI, Swanson GT, Swanger SA, Greger IH, Nakagawa T, McBain CJ, Jayaraman V, Low CM, Dell'Acqua ML, Diamond JS, Camp CR, Perszyk RE, Yuan H, Traynelis SF. Structure, function, and pharmacology of glutamate receptor ion channels[J]. Pharmacol Rev, 2021, 73:298-487.
[20] Lee CH, Lü W, Michel JC, Goehring A, Du J, Song X, Gouaux E. NMDA receptor structures reveal subunit arrangement and pore architecture[J]. Nature, 2014, 511:191-197.
[21] Karakas E, Furukawa H. Crystal structure of a heterotetrameric NMDA receptor ion channel[J]. Science, 2014, 344:992-997.
[22] Vieira MM, Jeong J, Roche KW. The role of NMDA receptor and neuroligin rare variants in synaptic dysfunction underlying neurodevelopmental disorders[J]. Curr Opin Neurobiol, 2021, 69:93-104.
[23] Xu XX, Luo JH. Mutations of N-methyl-D-aspartate receptor subunits in epilepsy[J]. Neurosci Bull, 2018, 34:549-565.
[24] Swanger SA, Chen W, Wells G, Burger PB, Tankovic A, Bhattacharya S, Strong KL, Hu C, Kusumoto H, Zhang J, Adams DR, Millichap JJ, Petrovski S, Traynelis SF, Yuan H. Mechanistic insight into NMDA receptor dysregulation by rare variants in the GluN2A and GluN2B agonist binding domains[J]. Am J Hum Genet, 2016, 99:1261-1280.
[25] Yuan H, Hansen KB, Zhang J, Pierson TM, Markello TC, Fajardo KV, Holloman CM, Golas G, Adams DR, Boerkoel CF, Gahl WA, Traynelis SF. Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy[J]. Nat Commun, 2014, 5:3251.
[26] Chen W, Tankovic A, Burger PB, Kusumoto H, Traynelis SF, Yuan H. Functional evaluation of a De Novo GRIN2A mutation identified in a patient with profound global developmental delay and refractory epilepsy[J]. Mol Pharmacol, 2017, 91:317-330.
[27] Venkateswaran S, Myers KA, Smith AC, Beaulieu CL, Schwartzentruber JA, Majewski J, Bulman D, Boycott KM, Dyment DA; FORGE Canada Consortium. Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel, de novo GRIN2A mutation[J]. Epilepsia, 2014, 55:e75-79.
[28] Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, Boutry-Kryza N, Salmi M, Tsintsadze T, Addis L, Motte J, Wright S, Tsintsadze V, Michel A, Doummar D, Lascelles K, Strug L, Waters P, de Bellescize J, Vrielynck P, de Saint Martin A, Ville D, Ryvlin P, Arzimanoglou A, Hirsch E, Vincent A, Pal D, Burnashev N, Sanlaville D, Szepetowski P. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction[J]. Nat Genet, 2013, 45:1061-1066.
[29] Lemke JR, Lal D, Reinthaler EM, Steiner I, Nothnagel M, Alber M, Geider K, Laube B, Schwake M, Finsterwalder K, Franke A, Schilhabel M, Jähn JA, Muhle H, Boor R, Van Paesschen W, Caraballo R, Fejerman N, Weckhuysen S, De Jonghe P, Larsen J, Møller RS, Hjalgrim H, Addis L, Tang S, Hughes E, Pal DK, Veri K, Vaher U, Talvik T, Dimova P, Guerrero López R, Serratosa JM, Linnankivi T, Lehesjoki AE, Ruf S, Wolff M, Buerki S, Wohlrab G, Kroell J, Datta AN, Fiedler B, Kurlemann G, Kluger G, Hahn A, Haberlandt DE, Kutzer C, Sperner J, Becker F, Weber YG, Feucht M, Steinböck H, Neophythou B, Ronen GM, Gruber-Sedlmayr U, Geldner J, Harvey RJ, Hoffmann P, Herms S, Altmüller J, Toliat MR, Thiele H, Nürnberg P, Wilhelm C, Stephani U, Helbig I, Lerche H, Zimprich F, Neubauer BA, Biskup S, von Spiczak S. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes[J]. Nat Genet, 2013, 45:1067-1072.
[30] Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes[J]. PLoS Genet, 2013, 9:e1003709.
[31] Strehlow V, Heyne HO, Vlaskamp DRM, Marwick KFM, Rudolf G, de Bellescize J, Biskup S, Brilstra EH, Brouwer OF, Callenbach PMC, Hentschel J, Hirsch E, Kind PC, Mignot C, Platzer K, Rump P, Skehel PA, Wyllie DJA, Hardingham GE, van Ravenswaaij-Arts CMA, Lesca G, Lemke JR; GRIN2A Study Group. GRIN2A-related disorders:genotype and functional consequence predict phenotype[J]. Brain, 2019, 142:80-92.
[32] Samanta D. GRIN2A-related epilepsy and speech disorders:a comprehensive overview with a focus on the role of precision therapeutics[J]. Epilepsy Res, 2023, 189:107065.
[33] Gao K, Tankovic A, Zhang Y, Kusumoto H, Zhang J, Chen W, XiangWei W, Shaulsky GH, Hu C, Traynelis SF, Yuan H, Jiang Y. A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia[J]. PLoS One, 2017, 12:e0170818.
[34] Tascón-Arcila J, Rojas-Jiménez S, Cornejo-Sánchez D, Gómez-Builes P, Ucroz-Benavides A, Holguín BM, Restrepo-Arbeláez D, Gómez-Castillo C, Solarte-Mia R, Cornejo-Ochoa W, Pineda-Trujillo N. Differential clinical features in colombian patients with rolandic epilepsy and suggestion of unlikely association with GRIN2A, RBFOX1, or RBFOX3 gene variants[J]. J Child Neurol, 2021, 36:875-882.
[35] Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I, Milh M, Kortüm F, Fritsch A, Pientka FK, Hellenbroich Y, Kalscheuer VM, Kohlhase J, Moog U, Rappold G, Rauch A, Ropers HH, von Spiczak S, Tönnies H, Villeneuve N, Villard L, Zabel B, Zenker M, Laube B, Reis A, Wieczorek D, Van Maldergem L, Kutsche K. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes[J]. Nat Genet, 2010, 42:1021-1026.
[36] Helbig I, Ellis CA. Personalized medicine in genetic epilepsies:possibilities, challenges, and new frontiers[J]. Neuropharmacology, 2020, 172:107970.
[37] Sivakumar S, Ghasemi M, Schachter SC. Targeting NMDA receptor complex in management of epilepsy[J]. Pharmaceuticals (Basel), 2022, 15:1297.
[38] Suvekbala V, Ramachandran H, Veluchamy A, Mascarenhas MAB, Ramprasath T, Nair MKC, Garikipati VNS, Gundamaraju R, Subbiah R. The promising epigenetic regulators for refractory epilepsy:an adventurous road ahead[J]. Neuromolecular Med, 2022[.Epub ahead of print]
[39] Ahmad MA, Pottoo FH, Akbar M. Gene therapy repairs for the epileptic brain:potential for treatment and future directions[J]. Curr Gene Ther, 2020, 19:367-375.
[40] Amador A, Bostick CD, Olson H, Peters J, Camp CR, Krizay D, Chen W, Han W, Tang W, Kanber A, Kim S, Teoh J, Sah M, Petri S, Paek H, Kim A, Lutz CM, Yang M, Myers SJ, Bhattacharya S, Yuan H, Goldstein DB, Poduri A, Boland MJ, Traynelis SF, Frankel WN. Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice[J]. Brain, 2020, 143:2039-2057.
[41] Tang W, Liu D, Traynelis SF, Yuan H. Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders[J]. Neuropharmacology, 2020, 177:108247.
[42] Sarigecili E, Direk MC, Komur M, Bozdogan ST, Okuyaz C. Identification of a novel mutation in GRIN2A gene with global developmental delay and refractory epilepsy[J]. Ann Indian Acad Neurol, 2020, 23:696-699.
[43] Xu XX, Liu XR, Fan CY, Lai JX, Shi YW, Yang W, Su T, Xu JY, Luo JH, Liao WP. Functional investigation of a GRIN2A variant associated with rolandic epilepsy[J]. Neurosci Bull, 2018, 34:237-246.
[44] Krey I, von Spiczak S, Johannesen KM, Hikel C, Kurlemann G, Muhle H, Beysen D, Dietel T, Møller RS, Lemke JR, Syrbe S. L-serine treatment is associated with improvements in behavior, EEG, and seizure frequency in individuals with GRIN-related disorders due to null variants[J]. Neurotherapeutics, 2022, 19:334-341.
[45] Tang W, Beckley JT, Zhang J, Song R, Xu Y, Kim S, Quirk MC, Robichaud AJ, Diaz ES, Myers SJ, Doherty JJ, Ackley MA, Traynelis SF, Yuan H. Novel neuroactive steroids as positive allosteric modulators of NMDA receptors:mechanism, site of action, and rescue pharmacology on GRIN variants associated with neurological conditions[J]. Cell Mol Life Sci, 2023, 80:42.
[46] Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR, Markello T, Golas G, Simeonov DR, Holloman C, Tankovic A, Karamchandani MM, Schreiber JM, Mullikin JC, Tifft CJ, Toro C, Boerkoel CF, Traynelis SF, Gahl WA; PhD for the NISC Comparative Sequencing Program. GRIN2A mutation and early-onset epileptic encephalopathy:personalized therapy with memantine[J]. Ann Clin Transl Neurol, 2014, 1:190-198. |